Lyme Borreliosis

  • Jana HercogováEmail author


Lyme borreliosis is an inflammatory disease caused by the spirochaete Borrelia burgdorferi which is transmitted by tick (mainly of the genus Ixodes). It is an anthropozoonosis which manifests itself as a multisystem disorder of the skin and other organs (joints, nerves, heart, eye). Antibiotic therapy should be started as soon as possible after the diagnosis has been made. The drugs of choice for oral treatment of Lyme borreliosis are doxycycline and amoxicillin and for parenteral treatment ceftriaxone, cefotaxime and penicillin G.

Further Reading

  1. Aberer E, Keldorfer M, Binder B, Shauperl H. The outcome of Lyme borreliosis in children. Wien Klin Wochenschr. 1999;111(22–23):941–4.PubMedGoogle Scholar
  2. Arnez M, Radsel-Medvescek A, Pieterski-Rigler D, et al. Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wien Klin Wochenschr. 1999;111(22–23):916–22.PubMedGoogle Scholar
  3. Biesiada G, Czepiel J, Leśniak MR, Garlicki A, Mach T. Lyme disease review. Arch Med Sci. 2012;8(6):978–82.CrossRefGoogle Scholar
  4. Cunha BA. Minocycline versus doxycycline in the treatment of Lyme neuroborreliosis. Clin Infect Dis. 2000;30(1):237–8.CrossRefGoogle Scholar
  5. Dotevall I, Hagberg I. Adverse effects of minocycline versus doxycycline in the treatment of Lyme neuroborreliosis. Clin Infect Dis. 2000;30(1):410–1.CrossRefGoogle Scholar
  6. Eriksson P, Schröder MT, Niiranen K, Nevanlinna A, Panelius J, Ranki A. The many faces of solitary and multiple erythema migrans. Acta Derm Venereol. 2013;93(6):693–700.CrossRefGoogle Scholar
  7. Gilmore Jr RD, Mbow ML. Conformational nature of the Borrelia burgdorferi B31 outer surface protein C protective epitope. Infect Immun. 1999;67(10):5463–9.PubMedPubMedCentralGoogle Scholar
  8. Hayney MS, Grunske MM, Boh LE. Lyme disease prevention and vaccine prophylaxis. Ann Pharmacother. 1999;33:723–9.CrossRefGoogle Scholar
  9. Hercogova J, Brzonova I. Lyme disease in central Europe. Curr Opin Infect Dis. 2001;14:133.CrossRefGoogle Scholar
  10. Hercogová J, Vaňousová D. Syphilis and borreliosis during pregnancy. Dermatol Ther. 2008;21(3):205–9.CrossRefGoogle Scholar
  11. Khatchikian CE, Nadelman RB, Nowakowski J, Schwartz I, Wormser GP, Brisson D. Evidence for strain-specific immunity in patients treated for early Lyme disease. Infect Immun. 2014;82:1408–13.CrossRefGoogle Scholar
  12. Klempner MS, Baker PJ, Shapiro ED, Marques A, Dattwyler RJ, Halperin JJ, Wormser GP. Treatment trials for post-Lyme disease symptoms revisited. Am J Med. 2013;126(8):665–9.CrossRefGoogle Scholar
  13. Maraspin V, Lotric-Furlan S, Cimperman J, et al. Erythema migrans in the immunocompromised host. Wien Klin Wochenschr. 1999;111(22–23):923–32.PubMedGoogle Scholar
  14. Moniuszko A, Pancewicz S, Czupryna P, Dunaj J, Guziejko K, Zajkowska J. Erythema migrans as a patognomic symptom of Lyme disease [Article in Polish]. Pol Merkur Lekarski. 2013;35(208):230–2.PubMedGoogle Scholar
  15. Mullegger RR, Glatz M. Is serological follow-up useful for patients with cutaneous Lyme borreliosis? Curr Probl Dermatol. 2009;37:178–82.CrossRefGoogle Scholar
  16. Oksi J, Marjamaki M, Nikoskelainen J, Viljanen MK. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann Med. 1999;31(3):225–32.CrossRefGoogle Scholar
  17. Pícha D, Moravcová L, Vaňousová D, Hercoogvá J, Blechová Z. DNA persistence after treatment of Lyme borreliosis. Folia Microbiol (Praha). 2014;59:115–25.CrossRefGoogle Scholar
  18. Roupakias S, Mitsakou P, Nimer AA. Tick removal. J Prev Med Hyg. 2011;52(1):40–4.PubMedGoogle Scholar
  19. Seltyer EG, Gerber MA, Cartter ML, et al. Long-term outcomes of persons with Lyme disease. JAMA. 2000;283(5):609–16.CrossRefGoogle Scholar
  20. Shadick NA, Phillips CB, Sangha O, et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med. 1999;131(12):919–26.CrossRefGoogle Scholar
  21. Stanek G, Breier F, Menyinger G, et al. Erythema migrans and serodiagnosis by enzyme immunoassay and immunoblot with three Borrelia species. Wien Klin Wochenschr. 1999;111(22–23):951–6.PubMedGoogle Scholar
  22. Wahlberg P. Vaccination against Lyme borreliosis. Ann Med. 1999;31:233–5.CrossRefGoogle Scholar
  23. Warshafsky S, Nowakowski J, Nadelman RB, et al. Efficacy of antibiotic prophylaxis for prevention of Lyme disease. J Gen Intern Med. 1996;11:329–33.CrossRefGoogle Scholar
  24. Wormser GP, Daniels TJ, Bittker S, Cooper D, Wang G, Pavia CS. Failure of topical antibiotics to prevent disseminated Borrelia burgdorferi infection following a tick bite in C3H/HeJ mice. J Infect Dis. 2012;205(6):991–4.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Chairwoman, Dermatovenereology Department, 2nd Medical FacultyCharles University, Institute of Clinical and Experimental Medicine, Bulovka HospitalPraha 8, PragueCzech Republic

Personalised recommendations